Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum, et al.
Blood (2022) Vol. 140, Iss. 12, pp. 1345-1377
Open Access | Times Cited: 1700

Showing 1-25 of 1700 citing articles:

Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2023) Vol. 98, Iss. 3, pp. 502-526
Open Access | Times Cited: 212
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
Harry P. Erba, Pau Montesinos, Hee‐Je Kim, et al.
The Lancet (2023) Vol. 401, Iss. 10388, pp. 1571-1583
Closed Access | Times Cited: 193
Acute myeloid leukaemia
Courtney D. DiNardo, Harry P. Erba, Sylvie D. Freeman, et al.
The Lancet (2023) Vol. 401, Iss. 10393, pp. 2073-2086
Open Access | Times Cited: 165
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Eric J. Duncavage, Adam Bagg, Robert P. Hasserjian, et al.
Blood (2022) Vol. 140, Iss. 21, pp. 2228-2247
Open Access | Times Cited: 140
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant
Laura W. Dillon, Gege Gui, Kristin Page, et al.
JAMA (2023) Vol. 329, Iss. 9, pp. 745-745
Open Access | Times Cited: 94
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Naval Daver, Abhishek Maiti, Tapan M. Kadia, et al.
Cancer Discovery (2022) Vol. 12, Iss. 11, pp. 2516-2529
Open Access | Times Cited: 92
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
Curtis A. Lachowiez, Sanam Loghavi, Zhihong Zeng, et al.
Blood Cancer Discovery (2023) Vol. 4, Iss. 4, pp. 276-293
Open Access | Times Cited: 69
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3
Mark J. Levis, Mehdi Hamadani, Brent R. Logan, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 15, pp. 1766-1775
Open Access | Times Cited: 66
Clonal haematopoiesis and dysregulation of the immune system
Roger Belizaire, Waihay J. Wong, Michelle L. Robinette, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 9, pp. 595-610
Closed Access | Times Cited: 56
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
Christian Rausch, Maja Rothenberg‐Thurley, Annika Dufour, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1234-1244
Open Access | Times Cited: 45
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
Krzysztof Mrózek, Jessica Kohlschmidt, James S. Blachly, et al.
Leukemia (2023) Vol. 37, Iss. 4, pp. 788-798
Open Access | Times Cited: 41
AML classification in the year 2023: How to avoid a Babylonian confusion of languages
Sandra Huber, Constance Baer, Stephan Hütter, et al.
Leukemia (2023) Vol. 37, Iss. 7, pp. 1413-1420
Open Access | Times Cited: 41
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial
Hartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
The Lancet Haematology (2023) Vol. 10, Iss. 7, pp. e495-e509
Closed Access | Times Cited: 40
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission
Jad Othman, Nicola Potter, Adam Ivey, et al.
Blood (2024) Vol. 143, Iss. 19, pp. 1931-1936
Closed Access | Times Cited: 28
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
Jad Othman, Nicola Potter, Adam Ivey, et al.
Blood (2024) Vol. 144, Iss. 7, pp. 714-728
Closed Access | Times Cited: 23
Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine
Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, et al.
Blood (2024) Vol. 144, Iss. 21, pp. 2211-2222
Open Access | Times Cited: 22
A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia
Anna Candoni, Gabriele Coppola
Hematology Reports (2024) Vol. 16, Iss. 2, pp. 244-254
Open Access | Times Cited: 21
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
Hartmut Döhner, Courtney D. DiNardo, Frederick Appelbaum, et al.
Blood (2024) Vol. 144, Iss. 21, pp. 2169-2173
Closed Access | Times Cited: 20
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
Jan‐Niklas Eckardt, Waldemar Hahn, Christoph Röllig, et al.
npj Digital Medicine (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 19
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
Wei‐Ying Jen, Hagop M. Kantarjian, Tapan M. Kadia, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 30-47
Open Access | Times Cited: 17
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 10, pp. 1158-1168
Open Access | Times Cited: 16
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia
Laura W. Dillon, Gege Gui, Niveditha Ravindra, et al.
JAMA Oncology (2024) Vol. 10, Iss. 8, pp. 1104-1104
Open Access | Times Cited: 16
Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update
Yu Wang, Ying‐Jun Chang, Jing Chen, et al.
Cancer Letters (2024) Vol. 605, pp. 217264-217264
Closed Access | Times Cited: 16
Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation
Xavier Thomas
Oncology and Therapy (2024) Vol. 12, Iss. 1, pp. 57-72
Open Access | Times Cited: 15
SF3B1 mutations provide genetic vulnerability to copper ionophores in human acute myeloid leukemia
Céline Moison, Deanne Gracias, Julie Schmitt, et al.
Science Advances (2024) Vol. 10, Iss. 12
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top